Brian Dorsey

CIK: 0001380762

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)3 (37.5%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SPRY

ARS Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

SPRY
ARS Pharmaceuticals, Inc.
Jan 2, 2026
Award(A)
Stock option (right to buy)
Direct
240K shares-
SPRY
ARS Pharmaceuticals, Inc.
Nov 13, 2025
Sale(S)
Direct
21.8K shares at avg. $8.71$190K
SPRY
ARS Pharmaceuticals, Inc.
Nov 13, 2025
Exercise(M)
Direct
21.8K shares at avg. $0.64$14K
SPRY
ARS Pharmaceuticals, Inc.
Jan 2, 2025
Award(A)
Stock option (right to buy)
Direct
261.9K shares-
SPRY
ARS Pharmaceuticals, Inc.
Dec 12, 2024
Exercise(M)
Direct
25K shares at avg. $0.64$16K
SPRY
ARS Pharmaceuticals, Inc.
Dec 12, 2024
Sale(S)
Direct
25K shares at avg. $12.30$307K
SPRY
ARS Pharmaceuticals, Inc.
Dec 11, 2024
Sale(S)
Direct
15K shares at avg. $12.43$186K
SPRY
ARS Pharmaceuticals, Inc.
Dec 11, 2024
Exercise(M)
Direct
15K shares at avg. $0.64$10K

		Type	Shares	Price		Ownership
Jan 2, 2026	SPRY ARS Pharmaceuticals, Inc.	Award(A) Stock option (right to buy)	240,000	-	-	Direct
Nov 13, 2025	SPRY ARS Pharmaceuticals, Inc.	Sale(S)	21,828	$8.71	$190,050	Direct
Nov 13, 2025	SPRY ARS Pharmaceuticals, Inc.	Exercise(M)	21,828	$0.64	$13,970	Direct
Jan 2, 2025	SPRY ARS Pharmaceuticals, Inc.	Award(A) Stock option (right to buy)	261,900	-	-	Direct
Dec 12, 2024	SPRY ARS Pharmaceuticals, Inc.	Exercise(M)	25,000	$0.64	$16,000	Direct
Dec 12, 2024	SPRY ARS Pharmaceuticals, Inc.	Sale(S)	25,000	$12.30	$307,433	Direct
Dec 11, 2024	SPRY ARS Pharmaceuticals, Inc.	Sale(S)	15,000	$12.43	$186,426	Direct
Dec 11, 2024	SPRY ARS Pharmaceuticals, Inc.	Exercise(M)	15,000	$0.64	$9,600	Direct

1-8 of 8 transactions

About Dorsey Brian

Dorsey Brian (SEC CIK 0001380762) files insider reports with the SEC as Chief Operating Officer of ARS Pharmaceuticals, Inc. (SPRY).

Signal8 holds 4 ownership filings by Dorsey Brian, all Form 4s, filed between Dec 13, 2024 and Jan 5, 2026. Those filings report 8 transactions, from Dec 11, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dorsey Brian's filings is in SAN DIEGO, CA.

Recent filings by Dorsey Brian

Jan 2, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
Nov 13, 2025: Open-market sale of SPRY shares (Form 4, code S).
Nov 13, 2025: Option exercise of SPRY shares (Form 4, code M).
Jan 2, 2025: Grant or award of SPRY derivative securities (Form 4, code A).
Dec 12, 2024: Option exercise of SPRY shares (Form 4, code M).

Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)

Casale Donn, President and CEO
Smith Margaret Ekins, Chief Commercial Officer
RA CAPITAL MANAGEMENT, L.P., Director
Dadoo Rajeev, Director
Shah Pratik, Director
Kelly Michael, Director

How to read Form 4 transaction codes